AIMD Insider Trading
Insider Ownership Percentage: 9.79%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $158,010.56
Ainos Share Price & Price History
Current Price: $1.88
Price Change: ▼ Price Decrease of -0.03 (-1.57%)
As of 02/9/2026 05:00 PM ET
Ainos Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/28/2026 | Carbon Nano Technology Taiwan | Major Shareholder | Sell | 46,000 | $2.17 | $99,820.00 | 989,925 |  |
| 1/9/2026 | Carbon Nano Technology Taiwan | Major Shareholder | Sell | 431 | $1.86 | $801.66 | 1,035,925 | |
| 1/8/2026 | Carbon Nano Technology Taiwan | Major Shareholder | Sell | 850 | $1.80 | $1,530.00 | 1,036,356 | |
| 10/6/2025 | Carbon Nano Technology Taiwan | Major Shareholder | Sell | 7,000 | $3.59 | $25,130.00 | 1,037,206 | |
| 10/2/2025 | Carbon Nano Technology Taiwan | Major Shareholder | Sell | 2,000 | $3.58 | $7,160.00 | 1,044,206 | |
| 6/27/2025 | Chun-Jung Tsai | Director | Sell | 2,000 | $2.50 | $5,000.00 | 276,999 | |
| 6/25/2025 | Chun-Jung Tsai | Director | Sell | 1,400 | $2.50 | $3,500.00 | 278,999 | |
| 6/25/2025 | Ting-Chuan Lee | Director | Sell | 578 | $2.55 | $1,473.90 | 285,707 | |
| 6/23/2025 | Chun-Jung Tsai | Director | Sell | 2,000 | $2.50 | $5,000.00 | 280,399 | |
| 6/19/2025 | Chun-Jung Tsai | Director | Sell | 2,180 | $2.75 | $5,995.00 | 282,399 | |
| 6/18/2025 | Chun-Jung Tsai | Director | Sell | 1,000 | $2.60 | $2,600.00 | 284,580 | |
SEC Filings (Institutional Ownership Changes) for Ainos (NASDAQ:AIMD)
Ainos Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/14/2025 | Two Sigma Investments LP | 23,008 | $80K | 0.0% | N/A | 0.482% |  |
Data available starting January 2016
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Read More on Ainos
Volume
41,193 shs
Average Volume
1,902,894 shs
Market Capitalization
$9.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.49
Who are the company insiders with the largest holdings of Ainos?
